Search Result

Results for "

Lipid metabolite

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Drug Metabolite (7) Endogenous Metabolite (19) Akt (1) Androgen Receptor (1) Antibiotic (1) Apoptosis (1) DNA/RNA Synthesis (1) ERK (1) Estrogen Receptor/ERR (1) GABA Receptor (1) HIV (1) Necroptosis (1) p38 MAPK (1) PKA (1) Potassium Channel (3) PPAR (4)
By Research Areas:	Cancer (2) Cardiovascular Disease (6) Infection (1) Inflammation/Immunology (3) Metabolic Disease (24) Neurological Disease (3)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Drug Metabolite Endogenous Metabolite

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-136346

2-Hydroxy atorvastatin lactone	Drug Metabolite	Cardiovascular Disease
2-Hydroxy atorvastatin lactone is a metabolite of Atorvastatin. Atorvastatin is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids .

HY-113378

3-Hydroxybutyric acid Maximum Cited Publications 6 Publications Verification β-Hydroxybutyric acid	Endogenous Metabolite	Metabolic Disease
3-Hydroxybutyric acid (β-Hydroxybutyric acid) is a metabolite that is elevated in type I diabetes. 3-Hydroxybutyric acid can modulate the properties of membrane lipids .

HY-157586

2-Linoleoyl-sn-glycero-3-phosphoethanolamine Lysophosphatidylethanolamine C18:2	Others	Others
2-Linoleoyl-sn-glycero-3-phosphoethanolamine (Lysophosphatidylethanolamine C18:2) is a kind of lipid metabolite, that can be used as biomarkers .

HY-W010452S1

3-Hydroxybutyric acid-13C4 sodium β-Hydroxybutyric acid-¹³C₄ sodium	Endogenous Metabolite	Metabolic Disease
3-Hydroxybutyric acid- ¹³C₄ (sodium) is the ¹³C labeled 3-Hydroxybutyric acid sodium (HY-W010452). 3-Hydroxybutyric acid sodium is a metabolite that is elevated in type I diabetes, and can modulate the properties of membrane lipids[1].

HY-W010452S2

3-Hydroxybutyric acid-13C2 sodium β-Hydroxybutyric acid-¹³C₂ sodium	Endogenous Metabolite	Metabolic Disease
3-Hydroxybutyric acid- ¹³C₂ (sodium) is the ¹³C labeled 3-Hydroxybutyric acid sodium (HY-W010452). 3-Hydroxybutyric acid sodium is a metabolite that is elevated in type I diabetes, and can modulate the properties of membrane lipids[1].

HY-W010452

3-Hydroxybutyric acid sodium Maximum Cited Publications 6 Publications Verification β-Hydroxybutyric acid sodium	Endogenous Metabolite	Metabolic Disease
3-Hydroxybutyric acid sodium (β-Hydroxybutyric acid sodium) is a metabolite that is elevated in type I diabetes. 3-Hydroxybutyric acid sodium can modulate the properties of membrane lipids .

HY-113147A

L-Palmitoylcarnitine chloride 1 Publications Verification	Potassium Channel Endogenous Metabolite	Cardiovascular Disease Metabolic Disease
L-Palmitoylcarnitine chloride, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine chloride inhibits K_ATP channel activity, without affecting the single channel conductance, through interaction with Kir6.2 .

HY-113147B

L-Palmitoylcarnitine TFA 1 Publications Verification	Endogenous Metabolite Potassium Channel	Cardiovascular Disease Metabolic Disease
L-Palmitoylcarnitine TFA, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine TFA inhibits K_ATP channel activity, without affecting the single channel conductance, through interaction with Kir6.2 .

HY-135594

4'-Raloxifene-β-D-glucopyranoside	Estrogen Receptor/ERR	Metabolic Disease
4'-Raloxifene-β-D-glucopyranoside, a metabolite of Raloxifene, is a benzothiophene glucuronidated at the 4' postion. 4'-Raloxifene-β-D-glucopyranoside is a selective and orally active estrogen receptor antagonist. 4'-Raloxifene-β-D-glucopyranoside can be used for inhibiting bone loss and resorption, and lowering lipid levels. 4'-Raloxifene-β-D-glucopyranoside, example 5, is extracted from patent US5567820A .

HY-E70240

3-Hydroxyoctadecanoyl-CoA

Endogenous Metabolite Metabolic Disease

3-Hydroxyoctadecanoyl-CoA is a metabolite of lipid metabolism .
HY-N7390

Cholesterol glucuronide

Endogenous Metabolite Metabolic Disease

Cholesterol glucuronide is an endogenous metabolite of lipid generated in the liver by UDP glucuonyltransferase .

3-Hydroxyoctadecanoyl-CoA	Endogenous Metabolite	Metabolic Disease
3-Hydroxyoctadecanoyl-CoA is a metabolite of lipid metabolism .

Cholesterol glucuronide	Endogenous Metabolite	Metabolic Disease
Cholesterol glucuronide is an endogenous metabolite of lipid generated in the liver by UDP glucuonyltransferase .

HY-113168

Butyrylcarnitine	Endogenous Metabolite	Others
Butyrylcarnitine is a metabolite in plasma, acts as a biomarker to improve the diagnosis and prognosis of heart failure, and is indicative of anomalous lipid and energy metabolism.

HY-P2200

Siamycin I BMY-29304	HIV Antibiotic	Infection Inflammation/Immunology
Siamycin I (BMY-29304), a 21-residue tricyclic peptide, is a secondary metabolite in actinomycetes. Siamycin I is a HIV fusion inhibitor with ED₅₀s of 0.05 to 5.7 μM for acute HIV type 1 (HIV-1) and HIV-2 infections. Siamycin I inhibits the gelatinase and gelatinase biosynthesis-activating pheromone (GBAP) signaling via the FsrC-FsrA two-component regulatory system in a noncompetitive manner. Siamycin I suppresses the expression of both fsrBDC and gelE-sprE transcripts. Siamycin I, a lasso peptide, interacts with lipid II and inhibits cell wall biosynthesis. Siamycin I, an antibiotic, has the potential for enterococcal infections research .

HY-113202

Stearoylcarnitine 1 Publications Verification	Endogenous Metabolite	Neurological Disease Metabolic Disease
Stearoylcarnitine, a fatty ester lipid molecule, is a human endogenous metabolite. Stearoylcarnitine acts as a metabolomics biomarker for early-onset-preeclampsia and late-onset-preeclampsia .

HY-113378S

3-Hydroxybutyric acid-d4 sodium β-Hydroxybutyric acid-d₄ (sodium)	Endogenous Metabolite	Metabolic Disease
3-Hydroxybutyric acid-d₄ (sodium) is the deuterium labeled 3-Hydroxybutyric acid. 3-Hydroxybutyric acid (β-Hydroxybutyric acid) is a metabolite that is elevated in type I diabetes. 3-Hydroxybutyric acid can modulate the properties of membrane lipids[1].

HY-W144096

Methyl 2,4,6-trihydroxybenzoate	Others	Metabolic Disease Cancer
Methyl 2,4,6-trihydroxybenzoate is a metabolite of 2,4,6-trihydroxybenzoate and exhibits properties as an antioxidant, lipid lowering and anticancer activities .

HY-136346S

Ortho-hydroxy atorvastatin lactone-d5	Drug Metabolite	Cardiovascular Disease
Ortho-hydroxy atorvastatin lactone-d₅ is deuterium labeled 2-Hydroxy atorvastatin lactone. 2-Hydroxy atorvastatin lactone is a metabolite of Atorvastatin. Atorvastatin is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids[1][2].

HY-W010452S

3-Hydroxybutyric acid-d2 sodium β-Hydroxybutyric acid-d₂ sodium	Endogenous Metabolite	Metabolic Disease
3-Hydroxybutyric acid-d₂ (sodium) is the deuterium labeled 3-Hydroxybutyric acid sodium[1]. 3-Hydroxybutyric acid sodium (β-Hydroxybutyric acid sodium) is a metabolite that is elevated in type I diabetes. 3-Hydroxybutyric acid sodium can modulate the properties of membrane lipids[2].

HY-B1415

Clofibric acid Chlorofibrinic acid	PPAR Drug Metabolite	Others
Clofibric acid (Chlorofibrinic acid), the pharmaceutically active metabolite of lipid regulators Clofibrate, Etofibrate and Etofyllinclofibrate, is a PPARα agonist which exhibits hypolipidemic effects. Clofibric acid also is an herbicide .

HY-14925

Lapaquistat 1 Publications Verification T-91485	Endogenous Metabolite Drug Metabolite	Metabolic Disease
Lapaquistat (T-91485), a cholesterol biosynthesis inhibitor, is the active metabolite of Lapaquistat acetate (HY-16274). Lapaquistat can decrease statin-induced myotoxicity in lipid-lowering therapy .

HY-126833B

Myristoyl coenzyme A triammonium 14:0 Coenzyme A	Others	Metabolic Disease
Myristoyl coenzyme A triammonium (14:0 Coenzyme A) is a type of long-chain acyl-CoA, which is the activated form of long-chain fatty acids and serves as a crucial lipid metabolite .

HY-126852

4-Hydroxy Atorvastatin lactone P-Hydroxyatorvastatin lactone; 4-ATL	Drug Metabolite	Metabolic Disease Inflammation/Immunology
4-Hydroxy Atorvastatin lactone is a metabolite of Atorvastatin (HY-B0589). Atorvastatin is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids .

HY-113202S

Stearoyl-L-carnitine-d3	Endogenous Metabolite	Neurological Disease Metabolic Disease
Stearoyl-L-carnitine-d₃ is the deuterium labeled Stearoylcarnitine. Stearoylcarnitine, a fatty ester lipid molecule, is a human endogenous metabolite. Stearoylcarnitine acts as a metabolomics biomarker for early-onset-preeclampsia and late-onset-preeclampsia[1].

HY-P3280

γ-Glu-Gly	Endogenous Metabolite	Metabolic Disease
γ-Glu-Gly, a γ-glutamyl dipeptide, is a human lipid metabolite.γ-Glu-Gly has a similar structure to GABA (γ-aminobutyric acid) and can act as an antagonist of excitatory amino acids .

HY-B1415S

Clofibric acid-d4 Chlorofibrinic acid-d₄	PPAR Drug Metabolite	Others
Clofibric acid-d₄ is the deuterium labeled Clofibric acid. Clofibric acid (Chlorofibrinic acid), the pharmaceutically active metabolite of lipid regulators Clofibrate, Etofibrate and Etofyllinclofibrate, is a PPARα agonist which exhibits hypolipidemic effects. Clofibric acid also is an herbicide[1][2][3].

HY-P3280A

γ-Glu-Gly TFA	Endogenous Metabolite	Metabolic Disease
γ-Glu-Gly TFA, a γ-glutamyl dipeptide, is a human lipid metabolite.γ-Glu-Gly TFA has a similar structure to GABA (γ-aminobutyric acid) and can act as an antagonist of excitatory amino acids .

HY-B1415R

Clofibric acid (Standard) Chlorofibrinic acid (Standard)	PPAR Drug Metabolite	Others
Clofibric acid (Standard) is the analytical standard of Clofibric acid. This product is intended for research and analytical applications. Clofibric acid (Chlorofibrinic acid), the pharmaceutically active metabolite of lipid regulators Clofibrate, Etofibrate and Etofyllinclofibrate, is a PPARα agonist which exhibits hypolipidemic effects. Clofibric acid also is an herbicide .

HY-Y0698

Thioacetamide Acetothioamide; TAA; Thiacetamide	Necroptosis	Inflammation/Immunology
Thioacetamide (TAA) is an indirect hepatotoxin and causes parenchymal cell necrosis. Thioacetamide requires metabolic activation by microsomal CYP2E1 to thioacetamide-S-oxide initially and then to thioacetamide-S-dioxide, which is a highly reactive metabolite, and its reactive metabolites covalently bind to proteins and lipids thereby causing oxidative stress and centrilobular necrosis. Thioacetamide can induce chronic liver fibrosis, encephalopathy and other events model .

HY-N2118

Bilobetin 1 Publications Verification	PPAR PKA Akt p38 MAPK ERK	Metabolic Disease
Bilobetin, an active component of Ginkgo biloba, can reduce blood lipids and improve the effects of insulin. Bilobetin ameliorated insulin resistance, increased the hepatic uptake and oxidation of lipids, reduced very-low-density lipoprotein triglyceride secretion and blood triglyceride levels, enhanced the expression and activity of enzymes involved in β-oxidation and attenuated the accumulation of triglycerides and their metabolites in tissues. Bilobetin also increased the phosphorylation, nuclear translocation and activity of PPARα accompanied by elevated cAMP level and PKA activity .

HY-113147AS

L-Palmitoylcarnitine-d3 hydrochloride	Potassium Channel Endogenous Metabolite	Cardiovascular Disease Metabolic Disease
L-Palmitoylcarnitine-d₃ (hydrochloride) is the deuterium labeled L-Palmitoylcarnitine hydrochloride. L-Palmitoylcarnitine hydrochloride, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine hydrochloride inhibits KATP channel activity, without affecting the single channel conductance, through interaction with Kir6.2[1].

HY-N1967

Dihydrocurcumin
Dihydrocurcumin, a major metabolites of curcumin, reduces lipid accumulation and oxidative stress. Dihydrocurcumin regulates mRNA and protein expression levels of SREBP-1C, PNPLA3 and PPARα, increases protein expression levels of pAKT and PI3K, and reduced the levels of cellular NO and ROS via Nrf2 signaling pathways .

HY-113314

AFMK	Endogenous Metabolite	Cancer
AFMK, antioxidant metabolite of Melatonin, attenuates X-ray-induced oxidative damage to DNA, proteins and lipids in mice. AFMK is a poorer scavenger. The pK_a of AFMK at physiological pH is 8.7. Antioxidant capacity . AFMK improves the anti-tumor effect of Gemcitabine in PANC-1 cells through the modulation of apoptotic pathway .

HY-139427

3-Methylglutaconic acid β-Methylglutaconic acid	GABA Receptor	Cardiovascular Disease Neurological Disease Metabolic Disease
3-Methylglutaconic acid is the major metabolites accumulating in 3-Methylglutaconic aciduria (MGTA). 3-Methylglutaconic acid can induce lipid oxidative damage and protein oxidative. 3-Methylglutaconic acid decreases the non-enzymatic antioxidant defenses in cerebral cortex supernatants to elicit oxidative stress in the cerebral cortex. 3-Methylglutaconic acid can be used for brain damage disease research .

HY-N6660

Trisdecanoin Tricaprin; Glyceryl tridecanoate	Endogenous Metabolite Androgen Receptor	Metabolic Disease
Trisdecanoin (Tricaprin; Glyceryl tridecanoate) is an orally available precursor of decanoic acid (DA precursor) that can be hydrolyzed to decanoic acid. Trisdecanoin and its metabolite capric acid not only provide the body with a quick source of energy, but can also affect lipid metabolism. Trisdecanoin is a major component of medium chain triglycerides (MCT), which has preventive or inhibitory properties for abdominal aortic aneurysms (AAA), inhibition of cardiovascular disease, and anti-androgen (NSAA) and anti-hyperglycemic properties. Trisdecanoin can be used as an additive in food, medicine and cosmetics .

HY-N6792

T-2 Toxin 1 Publications Verification T-2 Mycotoxin	Apoptosis DNA/RNA Synthesis	Metabolic Disease
T-2 Toxin (T-2 Mycotoxin) is a toxic trichothecene mycotoxin produced by various Fusarium species in feedstuffs and cereal grains, LD₅₀ values of T-2 Toxin in mice and rats are 5.2 and 1.5 mg/kg BW ^a,respectively . T-2 Toxin (T-2 Mycotoxin) can be transformed into a variety of metabolite, the typical metabolites of T-2 toxin in animals are HT-2 toxin and T-2-triol, which are hydrolysates . T-2 Toxin (T-2 Mycotoxin) is an inhibitor of protein synthesis resulting from binding peptidyltransferase, which is an integral part of the 60s ribosomal subunit. T-2 Toxin (T-2 Mycotoxin) inhibits the synthesis of DNA and RNA, interferes with the metabolism of membrane phospholipids, and increases the level of liver lipid peroxides . T-2 Toxin (T-2 Mycotoxin) induces apoptosis in the immune system, gastrointestinal tissues, and fetal tissues .

Cat. No.	Product Name

HY-L123

Human Metabolite Library	5990 compounds
Human metabolism is an integral part of cellular function that reflects individual differences in health, disease, diet, and lifestyle. Many health conditions such as obesity, diabetes, hypertension, heart disease, and cancer are associated with abnormal metabolic states. In the pathological state of the human body, metabolic pathways are significantly altered, resulting in aberrant levels of intermediates or end-products that can be viewed as potential diagnostic biomarkers or even therapeutic targets. Therefore, detection, identification and quantification of human metabolites are very important for drug metabolism research in drug development. MCE offers a unique collection of 5990 human metabolites, including endogenous metabolites and exogenous metabolites, covering multiple structure types, such as lipids, amino acids, nucleic acids, carbohydrates, organic acids, biogenic amines, vitamins,. MCE Human Metabolites Library is a helpful tool for studying the relationship between diseases and metabolism.

Human Metabolite Library

5990 compounds

Human metabolism is an integral part of cellular function that reflects individual differences in health, disease, diet, and lifestyle. Many health conditions such as obesity, diabetes, hypertension, heart disease, and cancer are associated with abnormal metabolic states. In the pathological state of the human body, metabolic pathways are significantly altered, resulting in aberrant levels of intermediates or end-products that can be viewed as potential diagnostic biomarkers or even therapeutic targets. Therefore, detection, identification and quantification of human metabolites are very important for drug metabolism research in drug development.

MCE offers a unique collection of 5990 human metabolites, including endogenous metabolites and exogenous metabolites, covering multiple structure types, such as lipids, amino acids, nucleic acids, carbohydrates, organic acids, biogenic amines, vitamins,. MCE Human Metabolites Library is a helpful tool for studying the relationship between diseases and metabolism.

HY-L072

Exosomes Compound Library	47 compounds
Exosomes are small membrane vesicles of endocytic origin that are secreted by most cells in culture. Exosomes contain nucleic acids, proteins, lipids, amino acids, and metabolites, etc. Their diverse constituents can reflect their cell of origin. Exosomes are associated with immune responses, viral pathogenicity, pregnancy, cardiovascular diseases, central nervous system-related diseases, and cancer progression. Proteins, metabolites, and nucleic acids delivered by exosomes into recipient cells effectively alter their biological response. Such exosome-mediated responses can be disease promoting or restraining. The biology of exosomes in disease is still emerging, and the number of studies addressing their utility in the diagnosis and treatment of various pathologies has increased substantially. MCE supplies a unique collection of 47 compounds with the activity of inhibiting or stimulating exsomes secretion/biosynthesis. MCE Exosomes Compound Library is a useful tool for exsomes research.

Exosomes Compound Library

47 compounds

Exosomes are small membrane vesicles of endocytic origin that are secreted by most cells in culture. Exosomes contain nucleic acids, proteins, lipids, amino acids, and metabolites, etc. Their diverse constituents can reflect their cell of origin. Exosomes are associated with immune responses, viral pathogenicity, pregnancy, cardiovascular diseases, central nervous system-related diseases, and cancer progression. Proteins, metabolites, and nucleic acids delivered by exosomes into recipient cells effectively alter their biological response. Such exosome-mediated responses can be disease promoting or restraining.

The biology of exosomes in disease is still emerging, and the number of studies addressing their utility in the diagnosis and treatment of various pathologies has increased substantially. MCE supplies a unique collection of 47 compounds with the activity of inhibiting or stimulating exsomes secretion/biosynthesis. MCE Exosomes Compound Library is a useful tool for exsomes research.

γ-Glu-Gly	Endogenous Metabolite	Metabolic Disease
γ-Glu-Gly, a γ-glutamyl dipeptide, is a human lipid metabolite.γ-Glu-Gly has a similar structure to GABA (γ-aminobutyric acid) and can act as an antagonist of excitatory amino acids .

Siamycin I BMY-29304	HIV Antibiotic	Infection Inflammation/Immunology
Siamycin I (BMY-29304), a 21-residue tricyclic peptide, is a secondary metabolite in actinomycetes. Siamycin I is a HIV fusion inhibitor with ED₅₀s of 0.05 to 5.7 μM for acute HIV type 1 (HIV-1) and HIV-2 infections. Siamycin I inhibits the gelatinase and gelatinase biosynthesis-activating pheromone (GBAP) signaling via the FsrC-FsrA two-component regulatory system in a noncompetitive manner. Siamycin I suppresses the expression of both fsrBDC and gelE-sprE transcripts. Siamycin I, a lasso peptide, interacts with lipid II and inhibits cell wall biosynthesis. Siamycin I, an antibiotic, has the potential for enterococcal infections research .

γ-Glu-Gly TFA	Endogenous Metabolite	Metabolic Disease
γ-Glu-Gly TFA, a γ-glutamyl dipeptide, is a human lipid metabolite.γ-Glu-Gly TFA has a similar structure to GABA (γ-aminobutyric acid) and can act as an antagonist of excitatory amino acids .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-113378

3-Hydroxybutyric acid Maximum Cited Publications 6 Publications Verification β-Hydroxybutyric acid	Structural Classification Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
3-Hydroxybutyric acid (β-Hydroxybutyric acid) is a metabolite that is elevated in type I diabetes. 3-Hydroxybutyric acid can modulate the properties of membrane lipids .

HY-W010452

3-Hydroxybutyric acid sodium Maximum Cited Publications 6 Publications Verification β-Hydroxybutyric acid sodium	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
3-Hydroxybutyric acid sodium (β-Hydroxybutyric acid sodium) is a metabolite that is elevated in type I diabetes. 3-Hydroxybutyric acid sodium can modulate the properties of membrane lipids .

HY-113147A

L-Palmitoylcarnitine chloride 1 Publications Verification	Cardiovascular Disease Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Potassium Channel Endogenous Metabolite
L-Palmitoylcarnitine chloride, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine chloride inhibits K_ATP channel activity, without affecting the single channel conductance, through interaction with Kir6.2 .

HY-113147B

L-Palmitoylcarnitine TFA 1 Publications Verification	Cardiovascular Disease Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Disease Research Fields	Endogenous Metabolite Potassium Channel
L-Palmitoylcarnitine TFA, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine TFA inhibits K_ATP channel activity, without affecting the single channel conductance, through interaction with Kir6.2 .

HY-N7390

Cholesterol glucuronide	Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Steroids	Endogenous Metabolite
Cholesterol glucuronide is an endogenous metabolite of lipid generated in the liver by UDP glucuonyltransferase .

HY-113168

Butyrylcarnitine	Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Source classification Other Diseases Endogenous metabolite Disease Research Fields	Endogenous Metabolite
Butyrylcarnitine is a metabolite in plasma, acts as a biomarker to improve the diagnosis and prognosis of heart failure, and is indicative of anomalous lipid and energy metabolism.

HY-113202

Stearoylcarnitine 1 Publications Verification	Structural Classification Microorganisms Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Endogenous Metabolite
Stearoylcarnitine, a fatty ester lipid molecule, is a human endogenous metabolite. Stearoylcarnitine acts as a metabolomics biomarker for early-onset-preeclampsia and late-onset-preeclampsia .

HY-W144096

Methyl 2,4,6-trihydroxybenzoate	Classification of Application Fields Source classification Phenols Polyphenols Metabolic Disease Endogenous metabolite Disease Research Fields Cancer	Others
Methyl 2,4,6-trihydroxybenzoate is a metabolite of 2,4,6-trihydroxybenzoate and exhibits properties as an antioxidant, lipid lowering and anticancer activities .

HY-14925

Lapaquistat 1 Publications Verification T-91485	Structural Classification Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite Drug Metabolite
Lapaquistat (T-91485), a cholesterol biosynthesis inhibitor, is the active metabolite of Lapaquistat acetate (HY-16274). Lapaquistat can decrease statin-induced myotoxicity in lipid-lowering therapy .

HY-P3280

γ-Glu-Gly	Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
γ-Glu-Gly, a γ-glutamyl dipeptide, is a human lipid metabolite.γ-Glu-Gly has a similar structure to GABA (γ-aminobutyric acid) and can act as an antagonist of excitatory amino acids .

HY-P3280A

γ-Glu-Gly TFA	Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
γ-Glu-Gly TFA, a γ-glutamyl dipeptide, is a human lipid metabolite.γ-Glu-Gly TFA has a similar structure to GABA (γ-aminobutyric acid) and can act as an antagonist of excitatory amino acids .

HY-N2118

Bilobetin 1 Publications Verification	Structural Classification Flavonoids Classification of Application Fields Ginkgoaceae Source classification Phenols Polyphenols Metabolic Disease Plants Biflavones Disease Research Fields Ginkgo biloba	PPAR PKA Akt p38 MAPK ERK
Bilobetin, an active component of Ginkgo biloba, can reduce blood lipids and improve the effects of insulin. Bilobetin ameliorated insulin resistance, increased the hepatic uptake and oxidation of lipids, reduced very-low-density lipoprotein triglyceride secretion and blood triglyceride levels, enhanced the expression and activity of enzymes involved in β-oxidation and attenuated the accumulation of triglycerides and their metabolites in tissues. Bilobetin also increased the phosphorylation, nuclear translocation and activity of PPARα accompanied by elevated cAMP level and PKA activity .

HY-113314

AFMK	Structural Classification Alkaloids Classification of Application Fields Other Alkaloids Source classification Endogenous metabolite Disease Research Fields Cancer	Endogenous Metabolite
AFMK, antioxidant metabolite of Melatonin, attenuates X-ray-induced oxidative damage to DNA, proteins and lipids in mice. AFMK is a poorer scavenger. The pK_a of AFMK at physiological pH is 8.7. Antioxidant capacity . AFMK improves the anti-tumor effect of Gemcitabine in PANC-1 cells through the modulation of apoptotic pathway .

HY-N6660

Trisdecanoin Tricaprin; Glyceryl tridecanoate	Ketones, Aldehydes, Acids Source classification umbellularia californica Metabolic Disease Plants Lauraceae Disease Research Fields	Endogenous Metabolite Androgen Receptor
Trisdecanoin (Tricaprin; Glyceryl tridecanoate) is an orally available precursor of decanoic acid (DA precursor) that can be hydrolyzed to decanoic acid. Trisdecanoin and its metabolite capric acid not only provide the body with a quick source of energy, but can also affect lipid metabolism. Trisdecanoin is a major component of medium chain triglycerides (MCT), which has preventive or inhibitory properties for abdominal aortic aneurysms (AAA), inhibition of cardiovascular disease, and anti-androgen (NSAA) and anti-hyperglycemic properties. Trisdecanoin can be used as an additive in food, medicine and cosmetics .

HY-N6792

T-2 Toxin 1 Publications Verification T-2 Mycotoxin	Structural Classification Microorganisms Classification of Application Fields Terpenoids Sesquiterpenes Source classification Metabolic Disease Disease Research Fields	Apoptosis DNA/RNA Synthesis
T-2 Toxin (T-2 Mycotoxin) is a toxic trichothecene mycotoxin produced by various Fusarium species in feedstuffs and cereal grains, LD₅₀ values of T-2 Toxin in mice and rats are 5.2 and 1.5 mg/kg BW ^a,respectively . T-2 Toxin (T-2 Mycotoxin) can be transformed into a variety of metabolite, the typical metabolites of T-2 toxin in animals are HT-2 toxin and T-2-triol, which are hydrolysates . T-2 Toxin (T-2 Mycotoxin) is an inhibitor of protein synthesis resulting from binding peptidyltransferase, which is an integral part of the 60s ribosomal subunit. T-2 Toxin (T-2 Mycotoxin) inhibits the synthesis of DNA and RNA, interferes with the metabolism of membrane phospholipids, and increases the level of liver lipid peroxides . T-2 Toxin (T-2 Mycotoxin) induces apoptosis in the immune system, gastrointestinal tissues, and fetal tissues .

Cat. No.	Product Name	Chemical Structure

HY-113378S

3-Hydroxybutyric acid-d4 sodium
3-Hydroxybutyric acid-d₄ (sodium) is the deuterium labeled 3-Hydroxybutyric acid. 3-Hydroxybutyric acid (β-Hydroxybutyric acid) is a metabolite that is elevated in type I diabetes. 3-Hydroxybutyric acid can modulate the properties of membrane lipids[1].

HY-W010452S1

3-Hydroxybutyric acid-13C4 sodium
3-Hydroxybutyric acid- ¹³C₄ (sodium) is the ¹³C labeled 3-Hydroxybutyric acid sodium (HY-W010452). 3-Hydroxybutyric acid sodium is a metabolite that is elevated in type I diabetes, and can modulate the properties of membrane lipids[1].

HY-W010452S2

3-Hydroxybutyric acid-13C2 sodium
3-Hydroxybutyric acid- ¹³C₂ (sodium) is the ¹³C labeled 3-Hydroxybutyric acid sodium (HY-W010452). 3-Hydroxybutyric acid sodium is a metabolite that is elevated in type I diabetes, and can modulate the properties of membrane lipids[1].

HY-136346S

Ortho-hydroxy atorvastatin lactone-d5
Ortho-hydroxy atorvastatin lactone-d₅ is deuterium labeled 2-Hydroxy atorvastatin lactone. 2-Hydroxy atorvastatin lactone is a metabolite of Atorvastatin. Atorvastatin is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids[1][2].

HY-W010452S

3-Hydroxybutyric acid-d2 sodium
3-Hydroxybutyric acid-d₂ (sodium) is the deuterium labeled 3-Hydroxybutyric acid sodium[1]. 3-Hydroxybutyric acid sodium (β-Hydroxybutyric acid sodium) is a metabolite that is elevated in type I diabetes. 3-Hydroxybutyric acid sodium can modulate the properties of membrane lipids[2].

HY-113202S

Stearoyl-L-carnitine-d3
Stearoyl-L-carnitine-d₃ is the deuterium labeled Stearoylcarnitine. Stearoylcarnitine, a fatty ester lipid molecule, is a human endogenous metabolite. Stearoylcarnitine acts as a metabolomics biomarker for early-onset-preeclampsia and late-onset-preeclampsia[1].

HY-B1415S

Clofibric acid-d4
Clofibric acid-d₄ is the deuterium labeled Clofibric acid. Clofibric acid (Chlorofibrinic acid), the pharmaceutically active metabolite of lipid regulators Clofibrate, Etofibrate and Etofyllinclofibrate, is a PPARα agonist which exhibits hypolipidemic effects. Clofibric acid also is an herbicide[1][2][3].

HY-113147AS

L-Palmitoylcarnitine-d3 hydrochloride

L-Palmitoylcarnitine-d₃ (hydrochloride) is the deuterium labeled L-Palmitoylcarnitine hydrochloride. L-Palmitoylcarnitine hydrochloride, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine hydrochloride inhibits KATP channel activity, without affecting the single channel conductance, through interaction with Kir6.2[1].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Lipid metabolite

Inhibitors & Agonists

Screening Libraries

Peptides

NaturalProducts

Isotope-Labeled Compounds

Natural
Products